Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, Maira-Arce M, Ye X, Shi L, Guo S, Hamilton M, Bajorin DF. Witjes JA, et al. Among authors: ye x. Eur Urol Oncol. 2022 Oct;5(5):553-563. doi: 10.1016/j.euo.2022.02.003. Epub 2022 Mar 11. Eur Urol Oncol. 2022. PMID: 35288066 Free PMC article. Clinical Trial.
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN. Mesa RA, et al. Among authors: ye x. Hemasphere. 2021 Apr 29;5(5):e553. doi: 10.1097/HS9.0000000000000553. eCollection 2021 May. Hemasphere. 2021. PMID: 33969273 Free PMC article.
Treatment Satisfaction and Convenience for Patients With Atrial Fibrillation on Edoxaban or Vitamin K Antagonists After Transcatheter Aortic Valve Replacement: A Post Hoc Analysis from the ENVISAGE-TAVI AF Trial.
Hengstenberg C, Van Mieghem NM, Wang R, Ye X, Shi L, Guo S, Chen C, Jin J, Ye X, Dangas G, Unverdorben M. Hengstenberg C, et al. Among authors: ye x. Am J Cardiol. 2023 Dec 15;209:212-219. doi: 10.1016/j.amjcard.2023.09.091. Epub 2023 Oct 14. Am J Cardiol. 2023. PMID: 37848174 Free article. Clinical Trial.
Ophiocordyceps sinensis preparations combined with the renin-angiotensin system inhibitor for diabetic kidney disease treatment: an umbrella review of systematic reviews and network meta-analysis.
Xue X, Jin XY, Ye XL, Li KY, Li JX, Liu XH, Bai J, Liu Q, Zhang BR, Zou XR, Yuan J, Lu CL, Zhao FF, Liu JP, Wang XQ. Xue X, et al. Among authors: ye xl. Front Pharmacol. 2024 Apr 22;15:1360633. doi: 10.3389/fphar.2024.1360633. eCollection 2024. Front Pharmacol. 2024. PMID: 38716236 Free PMC article.
A comprehensive analysis of patients with cerebral arteriovenous malformation with headache: assessment of risk factors and treatment effectiveness.
Zhang H, Han H, Ma L, Li R, Li Z, Li A, Yuan K, Zhu Q, Wang C, Zhang Y, Zhang H, Gao D, Guo G, Kang S, Ye X, Li Y, Sun S, Wang H, Hao Q, Chen Y, Wang R, Chen X, Zhao Y; Registry of Multimodality Treatment for Brain Arteriovenous Malformation in Mainland China (MATCH). Zhang H, et al. Among authors: ye x. J Headache Pain. 2024 May 7;25(1):72. doi: 10.1186/s10194-024-01774-7. J Headache Pain. 2024. PMID: 38714978 Free PMC article.
Missed opportunities for treatment of inflammatory arthritis and factors associated with non-treatment: An observational cohort study in United States Veterans with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
Walsh JA, Pei S, Alexander S, Braaten T, Walker JH, Clewell J, Douglas KM, Penmetsa GK, Ye X, Breviu B, Cannon GW, Kunkel GA, Sauer BC. Walsh JA, et al. Among authors: ye x. Semin Arthritis Rheum. 2024 Mar 28;66:152436. doi: 10.1016/j.semarthrit.2024.152436. Online ahead of print. Semin Arthritis Rheum. 2024. PMID: 38714073
10,444 results
You have reached the last available page of results. Please see the User Guide for more information.